Pfizer (PFE) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to -$14.7 billion.
- Pfizer's Enterprise Value fell 5174.59% to -$14.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.7 billion, marking a year-over-year decrease of 5174.59%. This contributed to the annual value of -$20.2 billion for FY2024, which is 6255.64% down from last year.
- Pfizer's Enterprise Value amounted to -$14.7 billion in Q3 2025, which was down 5174.59% from -$12.9 billion recorded in Q2 2025.
- In the past 5 years, Pfizer's Enterprise Value registered a high of -$6.8 billion during Q2 2024, and its lowest value of -$44.5 billion during Q3 2023.
- Over the past 5 years, Pfizer's median Enterprise Value value was -$20.2 billion (recorded in 2024), while the average stood at -$22.3 billion.
- As far as peak fluctuations go, Pfizer's Enterprise Value plummeted by 15698.2% in 2021, and later skyrocketed by 8466.67% in 2024.
- Pfizer's Enterprise Value (Quarter) stood at -$30.8 billion in 2021, then rose by 27.04% to -$22.5 billion in 2022, then soared by 44.76% to -$12.4 billion in 2023, then crashed by 62.56% to -$20.2 billion in 2024, then rose by 27.22% to -$14.7 billion in 2025.
- Its last three reported values are -$14.7 billion in Q3 2025, -$12.9 billion for Q2 2025, and -$17.0 billion during Q1 2025.